Excision of viral reprogramming cassettes by Cre protein transduction enables rapid, robust and efficient derivation of transgene-free human induced pluripotent stem cells
© Kadari et al.; licensee BioMed Central Ltd. 2014
Received: 25 September 2013
Accepted: 12 March 2014
Published: 8 April 2014
Integrating viruses represent robust tools for cellular reprogramming; however, the presence of viral transgenes in induced pluripotent stem cells (iPSCs) is deleterious because it holds the risk of insertional mutagenesis leading to malignant transformation. Here, we combine the robustness of lentiviral reprogramming with the efficacy of Cre recombinase protein transduction to derive iPSCs devoid of transgenes. By genome-wide analysis and targeted differentiation towards the cardiomyocyte lineage, we show that transgene-free iPSCs are superior to iPSCs before Cre transduction. Our study provides a simple, rapid and robust protocol for the generation of clinical-grade iPSCs suitable for disease modeling, tissue engineering and cell replacement therapies.
Initial reports for generating induced pluripotent stem cells (iPSCs) involved retroviruses as a mode of transgene delivery . Although retroviruses are capable of reprogramming somatic cells to iPSCs, the clinical applicability of such iPSCs is limited due to the integrated transgenes carrying the risk of insertional mutagenesis  and tumor formation . Moreover, continuous expression of transgenes in iPSCs negatively affects pluripotency  and limits their differentiation potential . These effects have been shown by the inability to yield live chimeric mice and the diminished endodermal differentiation of iPSCs carrying transgenes . Alternative approaches were explored to obtain higher efficiency with minimal genetic modifications of the cells. Various protocols circumventing viral vectors have been published, including the use of transposons , episomal plasmids , synthetic mRNA , microRNAs , Sendai virus  as well as protein transduction [11–13]. iPSCs generated by these methods contain minimal or no genetic modifications and are generally more suitable for clinical applications than cells derived by virus-based protocols. However, still there is no gold standard for an iPSC reprogramming strategy since these non-integrating approaches exhibit limitations such as low reprogramming efficiencies, slow reprogramming kinetics, a narrow range of cell specificity, and poor reproducibility [14, 15]. In terms of robustness and efficacy, therefore, the retroviral and lentiviral system still represents the method of choice for iPSC derivation .
Early attempts to improve viral-based iPSC protocols included the use of polycistronic vectors. The core element of those vectors is a cassette, consisting of cDNAs of the four transcription factors, linked together via 2A self-cleaving peptide sequences [17, 18]. This strategy allows translation of four separate polypeptides from a single mRNA strand. Thus, instead of four viruses, a single construct is sufficient to induce cellular reprogramming. This approach decreases the risk of insertional mutagenesis. Various biomedical applications of iPSCs will not strictly require cells completely free from genetic modifications. Hence, a Cre-excisable lentiviral system would provide a rapid and easy alternative for the generation of transgene-free iPSC clones. The usage of polycistronic vectors harboring loxP sites allows transgene excision from iPSCs via transient expression of Cre recombinase . However, the reprogramming efficiency using these vectors was reported to be only 0.01% . In 2009 Sommer and colleagues reported an improved lentiviral vector to overcome this limitation by yielding a reprogramming efficiency of 0.1 to 1.5% . Moreover, the vector could also reprogram peripheral blood cells that are usually quite resistant towards reprogramming . However, deletion of the loxP-flanked transgene cassette requires introduction of Cre recombinase activity. This activity has been accomplished by either transfection of iPSCs with a Cre-encoding plasmid [19, 22] or using an adenoviral Cre construct [5, 23] and subsequent genetic identification of successfully recombined clones. More recently, transgene-free iPSCs were obtained by excising the transgene cassette by delivery of Cre mRNA . However, this protocol involves daily transfection of mRNA for a week to perform excision. This rather inefficient and laborious transfection and selection procedure makes Cre/loxP-based iPSC derivation less appealing for obtaining transgene-free iPSCs. In fact, efficient and reliable induction of Cre recombinase activity in loxP-modified iPSCs and subsequent selection of cleaned clones represents a roadblock for the widespread use of Cre-deletable iPSC systems.
Direct delivery of biologically active Cre protein has been shown to be a highly efficient and robust method for inducing Cre recombinase activity in mammalian cells [25–28]. We reported a cell-permeable recombinant Cre protein that was generated by fusing Cre with the cell-penetrating peptide TAT and a nuclear localization sequence . The TAT peptide confers cell permeability and the nuclear localization sequence targets the fusion protein to the nucleus. TAT-Cre was used for site-specific recombination in human embryonic stem cells (ESCs) with more than 90% recombination efficiency . Here, we show rapid derivation of transgene-free human iPSC clones by combining direct delivery of biologically active TAT-Cre protein with robust reprogramming by a lentiviral polycistronic vector. We demonstrate that transgene deletion renders iPSCs that resemble more human ESCs with respect to gene expression than transgene-harboring cells before deletion. Moreover, we show a strong enhancement of differentiation towards the cardiac lineage in transgene-free iPSCs as compared with loxP-modified iPSCs.
Materials and methods
Reprogramming of human fibroblasts and characterization of iPSCs
The human fibroblasts used in this study were obtained from a skin punch biopsy of a 24-year-old male after obtaining informed consent and ethical clearance by the ethics committee of the University of Würzburg, Germany (ethical report number 96/11, dated 10 June 2011). Human fibroblasts were infected with the Human STEMCCA Cre-Excisable constitutive polycistronic (OKSM) lentiviral vector  and were seeded on irradiated mouse embryonic fibroblasts in a reprogramming medium consisting of Dulbecco’s modified Eagle’s medium/F12 (Sigma-Aldrich, St. Louis, MO, USA) with 20% KnockOut Serum Replacement (Invitrogen, Carlsbad, CA, USA), 1 mM non-animal l-glutamine (Sigma-Aldrich), 0.1 mM β-mercaptoethanol (Sigma-Aldrich), 1% non-essential amino acids (Invitrogen), and 10 ng/ml basic fibroblast growth factor (Invitrogen). After 3 weeks, iPSC-like colonies were picked, expanded on matrigel-coated dishes and characterized for the pluripotency markers Oct4 (Santacruz Biotechnology, Finnell Street Dallas, Texas 75220 USA) and SSEA-4 (Millipore, Temecula, CA, USA) antibodies.
TAT-Cre treatment of human iPSCs
Human iPSCs were maintained on matrigel-coated dishes in mTeSR™1 (STEMCELL Technologies, Temecula, CA, USA) or PluriSTEM™ (EMD Millipore, Vancouver, BC, Canada) medium. Human iPSC colonies were treated with alphazyme (1 ml/well in a six-well plate; PAA, Linz, Austria) for 5 to 10 minutes to obtain single cells. Then 100,000 to 200,000 cells were seeded in each well of a six-well plate having mTeSR™1 or PluriSTEM™ medium with 10 μM Rock inhibitor (Y27632; Sigma-Aldrich) to prevent the cell apoptosis. Twenty-four hours later, the medium was changed to mTeSR™1 or PluriSTEM™ containing TAT–Cre (catalogue number SCR508; EMD Millipore) with different concentrations of 0.5 μM, 1 μM and 2 μM. Cells were incubated with TAT-Cre recombinant protein for 5 hours. Cells were grown for 1 week and colonies were expanded either monoclonally or polyclonally, and then polymerase chain reaction (PCR) was performed to assess transgene deletion. Transgene-deleted clones were expanded and characterized further by immunostaining and differentiation.
Excision of the reprogramming cassette
To confirm the transgene deletion, genomic DNA from TAT-Cre-treated subclones were isolated and PCR was performed with the following conditions: 95°C for 2 minutes; followed by 34 cycles of 94°C for 30 seconds, 60°C for 30 seconds, and 72°C for 45 seconds; followed by a single cycle of 72°C for 5 minutes using the primers WPRE forward, ATCATGCTATTGCTTCCCGTATGGC and WPRE reverse, GGAGATCCGACTCGTCTGAGG, and β-actin forward, GGCTACAGCTTCACCACCAC and β-actin reverse, CCACCTTCCAGCAGATGTGG.
For iPSC characterization, immunostaining was performed using Oct4 (1:100; Santacruz Biotechnology) and SSEA-4 (1:200; Millipore) antibodies. Briefly, cells were washed with phosphate-buffered saline (PBS), fixed with 4% paraformaldehyde for 15 minutes and permeabilized in PBS containing 0.1% Triton X-100 and 5% fetal calf serum for 30 minutes. Cells were then incubated overnight with the Oct4 and SSEA-4 antibodies. Next day, secondary antibodies Alexa 488 and Alexa 555 (1:1000; Life Technologies, Carlsbad, CA, USA) were used to detect and visualize the primary antibodies. All antibodies were diluted in blocking solution. Micrographs were taken with an Axiovert 200 M microscope (Carl Zeiss, Oberkochen, Badenwürttemberg, Germany). The above immunostaining protocol was also performed to characterize cardiomyocytes using cardiac Troponin T (cTNT, 1:100; Abcam, Cambridge, England) and α-actinin (1:200; Sigma-Aldrich) as a primary antibody and Alexa 488 as a secondary antibody.
Teratoma formation and karyotype analysis
Pluripotency was tested by injection of the test cell population into the testes of immune-deficient NOD/SCID mice. Then 0.5 × 106 to 5 × 106 cells were injected using a pulled glass capillary pipette that was advanced via the efferent ducts through the rete testis into the interstitial space of the testis. Animals were euthanized when palpable tumors were present or at 4 months after injection, whichever came first. The teratomas were fixed in 10% neutral buffered formalin, dehydrated (graded alcohols), cleared (xylene) and embedded with paraffin wax (formalin fixed paraffin embedded). Then 5 μm sections were cut, floated on a water bath and picked up on positively charged slides (Probe On Plus). Sections were then deparaffinized in three changes of xylene, rehydrated in a series of graded alcohols (100% × 2, 70% × 2, 30% × 2, distilled H2O × 2) and hematoxylin and eosin staining was performed. Karyotype analysis was performed on 20 G-banded metaphase cells for TAT-Cre excised human iPSC clone at p13 by Cell Line Genetics (Madiso, WI, USA).
Gene expression analysis
RNA was isolated using the RNeasy-Kit (Qiagen, Hilden, Germany). mRNA transcription levels were evaluated using the Human HT-12 array (version 4, revision 2; Qiagen, Hilden, Germany), which consists of 47,323 probes and described mRNA features. All samples were processed at least in duplicate to reduce signals arising from processing artifacts. Data processing was performed using the GenomeStudio suite version 2011.1 and the Gene expression module version 1.9.4 (both Illumina Inc., San Diego, CA, USA). Gene expression data analysis was carried out with the R and Bioconductor packages, and their intensities were quantile normalized. The differentially expressed genes were determined by applying the empirical Bayes test statistics, and the Benjamini–Hochberg false discovery method was used for multiple testing correction. Genes with fold-change >2 and P ≤ 0.5 were considered differentially expressed and were used for subsequent analysis. The data discussed in this publication have been deposited in the National Center for Biotechnology Information Gene Expression Omnibus [GEO:GSE55725].
Generation of the Cre reporter human iPSC line
Human iPSC line del-AR1034ZIMA (del-ARiPS) clone 1.4 was treated with alfazyme to obtain a single-cell suspension. Then 200,000 cells were seeded in one well of a six-well plate in mTeSR™1 medium with 10 μM Rock inhibitor. On the next day, cells were infected with lentivirus containing EF1α-Cre reporter–puromycin construct (modified from original construct  by replacing CMV promoter by EF1α promoter). Forty-eight hours later, the medium was changed to mTeSR™1 with puromycin (1 μg/ml) for 5 days to obtain colonies with stably integrated Cre reporter construct.
Cardiomyocyte differentiation of human iPSCs
Human iPSCs were maintained on matrigel-coated plates in mTeSR™1 medium until they reached 80% confluency. Cardiac differentiation was induced by Activin A (5 ng/ml), BMP4 (25 ng/ml) and Chir99021 (5 μM) in RPMI 1640 medium containing B27 and 2 mM glutamine as a basal medium for 3 days. From day 4, cells were kept in basal medium containing Wnt inhibitor XAV939 for 5 days followed by further culture in basal medium.
Cells (1 × 106) were trypsinized and fixed with 4% paraformaldehyde for 10 minutes. Cells were then washed with PBS, permeabilized in PBS containing 0.1% Triton X-100 and 5% fetal calf serum for 30 minutes and incubated for 2 hours with cTNT antibody (1:100; Abcam). No antibody was taken as a negative control. Cells were then washed once with PBS containing 0.1% Tween-20 and resuspended in PBS containing 0.1% Triton-X 100 and 5% fetal calf serum and secondary antibody Alexa 488 anti-mouse IgG (1:1,000; Life Technologies) for 1 hour in the dark. Finally, cells were washed again with PBS containing 0.1% Tween-20 and measured for FACS analysis. Analysis was performed by the Flow Jo program.
Overview of generation of transgene-free human iPSCs with TAT-Cre application
Assessment of TAT-Cre-mediated transgene deletion efficiency
Characterization of transgene-free iPSCs
Improved cardiac differentiation potential of transgene-free iPSCs
In this study we demonstrate an efficient way of obtaining iPSCs with minimal genetic modifications by combining the widely applied and robust lentiviral reprogramming approach with the highly efficient and less invasive TAT-Cre-mediated transgene deletion. Earlier studies have reported the deletion of transgenes by delivering Cre as a plasmid, as Adeno-Cre, or by mRNA transfection [5, 19, 22–24]. The protocol elaborated by Soldner and colleagues yielded only 16 transgene-deleted clones out of 180 analyzed after transfecting iPSCs with a Cre-encoding plasmid and subsequent selection either with green fluorescent protein fluorescence or puromycin . The relatively low efficiency might be due to the transient transfection of Cre, which is limiting intracellular DNA recombinase activity. Sommer and colleagues and Somers and colleagues used Adeno-Cre and Cre-IRES-Puro constructs respectively to achieve higher excision efficiencies [5, 22]. A more recent study by Awe and colleagues demonstrate transgene excision in iPSC clones with putative clinical grade status using Adeno-Cre-mediated transgene deletion. During their transgene excision analysis the authors obtained only one transgene-excised subclone out of six Adeno-Cre-treated clones . Furthermore, deletion approaches using Cre plasmids or Adeno-Cre constructs require transfection and subsequent selection of cells with Cre recombinase activity either by flow cytometry sorting or by antibiotic selection. Such relatively complicated steps are undesirable because they might be stressful to the cells . Moreover, there is the possibility that Cre-encoding plasmids or viral constructs integrate into the genome . More recently, the group of George Daley has reported transgene excision by transfecting loxP-modified iPSC with Cre-encoding mRNA. Notably, this procedure involves daily transfections of Cre mRNA for 4 hours up to 7 days, which again represents a complicated and stressful procedure for the cells. The protocol developed in our study, in contrast, requires just a single application of TAT-Cre recombinant protein for 5 hours due to its high recombination efficiency. By this, the use of TAT-Cre accelerates the process of obtaining transgene-free iPSCs with minimal technical complexity. During our analysis, transgene-free iPSCs remain pluripotent. Moreover, microarray analysis indicates enhancement in the quality of iPSCs, as transgene-excised iPSCs are more similar to human ESCs with respect to gene expression profiling, confirming previous studies . In fact, transgene-free iPSCs exhibit an improved differentiation potential . In our study, we show enhanced cardiac differentiation of TAT-Cre-treated polyclonal iPSCs. By this we show an improvement in differentiation capacity of a polyclonal cell population after the removal of transgenes with Cre-mediated recombination. This makes TAT-Cre protein an attractive tool to obtain transgene-free iPSCs even in a polyclonal manner as recently suggested , circumventing the laborious selection procedure of transgene-excised clones. In conclusion, our study provides a simple, rapid and robust protocol for the generation of superior transgene-free iPSCs suitable for disease modeling, drug and toxicity screening, as well as cell replacement therapies.
In summary, our study outlines efficient derivation of factor-free human iPSC lines by combinatorial use of the robust lentivirus human STEMCCA vector and highly efficient TAT-Cre protein transduction. We have shown enhanced quality of transgene-free iPSCs using microarray analysis and cardiac differentiation. Moreover, we show polyclonal expansion of transgene-deleted clones that circumvents laborious selection procedures and time-consuming analysis of subclones.
cardiac Troponin T
AR1034ZIMA transgene-free daughter clones of ARIPS iPSC clone 1
AR1034ZIMA loxP-flanked transgene ARiPS iPSC clone 1
- HES I3:
human ESC I3 line
embryonic stem cell
induced pluripotent stem cell
polymerase chain reaction.
The authors thank Gustavo Mostoslavsky (Boston University School of Medicine, USA) for providing the STEMCCA construct and Sarah Kittel-Schneider as well as Andreas Reif (Klinik und Poliklinik für Psychiatrie, Würzburg, Germany) for providing human fibroblasts. They would also like to thank Andrea Hofmann for helping to obtain gene expression data. The authors are indebted to Martina Gebhardt, Kathrin Vogt and Nicole Russ for excellent technical support and to all members of the Stem Cell Engineering Group for support and valuable discussions and critical reading of the manuscript. This work was supported by grants from the Deutsche Forschungsgemeinschaft DFG (ED79/1-2) and the German Ministry of Education and Research, BMBF (01 GN 0813) and by Merck KGaA, Darmstadt, Germany.
- Takahashi K, Yamanaka S: Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006, 126: 663-676. 10.1016/j.cell.2006.07.024.View ArticlePubMedGoogle Scholar
- Mikkers H, Berns A: Retroviral insertional mutagenesis: tagging cancer pathways. Adv Cancer Res. 2003, 88: 53-99.PubMedGoogle Scholar
- Okita K, Ichisaka T, Yamanaka S: Generation of germline-competent induced pluripotent stem cells. Nature. 2007, 448: 313-317. 10.1038/nature05934.View ArticlePubMedGoogle Scholar
- Kopp JL, Ormsbee BD, Desler M, Rizzino A: Small increases in the level of Sox2 trigger the differentiation of mouse embryonic stem cells. Stem Cells. 2008, 26: 903-911. 10.1634/stemcells.2007-0951.View ArticlePubMedGoogle Scholar
- Sommer CA, Sommer AG, Longmire TA, Christodoulou C, Thomas DD, Gostissa M, Alt FW, Murphy GJ, Kotton DN, Mostoslavsky G: Excision of reprogramming transgenes improves the differentiation potential of iPS cells generated with a single excisable vector. Stem Cells. 2010, 28: 64-74.PubMedGoogle Scholar
- Kaji K, Norrby K, Paca A, Mileikovsky M, Mohseni P, Woltjen K: Virus-free induction of pluripotency and subsequent excision of reprogramming factors. Nature. 2009, 458: 771-775. 10.1038/nature07864.PubMed CentralView ArticlePubMedGoogle Scholar
- Chou BK, Mali P, Huang X, Ye Z, Dowey SN, Resar LM, Zou C, Zhang YA, Tong J, Cheng L: Efficient human iPS cell derivation by a non-integrating plasmid from blood cells with unique epigenetic and gene expression signatures. Cell Res. 2011, 21: 518-529. 10.1038/cr.2011.12.PubMed CentralView ArticlePubMedGoogle Scholar
- Warren L, Manos PD, Ahfeldt T, Loh YH, Li H, Lau F, Ebina W, Mandal PK, Smith ZD, Meissner A, Daley GQ, Brack AS, Collins JJ, Cowan C, Schlaeger TM, Rossi DJ: Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell. 2010, 7: 618-630. 10.1016/j.stem.2010.08.012.PubMed CentralView ArticlePubMedGoogle Scholar
- Anokye-Danso F, Trivedi CM, Juhr D, Gupta M, Cui Z, Tian Y, Zhang Y, Yang W, Gruber PJ, Epstein JA, Morrisey EE: Highly efficient miRNA-mediated reprogramming of mouse and human somatic cells to pluripotency. Cell Stem Cell. 2011, 8: 376-388. 10.1016/j.stem.2011.03.001.PubMed CentralView ArticlePubMedGoogle Scholar
- Fusaki N, Ban H, Nishiyama A, Saeki K, Hasegawa M: Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome. Proc Jpn Acad Ser B Phys Biol Sci. 2009, 85: 348-362. 10.2183/pjab.85.348.PubMed CentralView ArticlePubMedGoogle Scholar
- Bosnali M, Edenhofer F: Generation of transducible versions of transcription factors Oct4 and Sox2. Biol Chem. 2008, 389: 851-861.View ArticlePubMedGoogle Scholar
- Kim D, Kim CH, Moon JI, Chung YG, Chang MY, Han BS, Ko S, Yang E, Cha KY, Lanza R, Kim KS: Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. Cell Stem Cell. 2009, 4: 472-476. 10.1016/j.stem.2009.05.005.PubMed CentralView ArticlePubMedGoogle Scholar
- Zhou H, Wu S, Joo JY, Zhu S, Han DW, Lin T, Trauger S, Bien G, Yao S, Zhu Y, Siuzdak G, Schöler HR, Duan L, Ding S: Generation of induced pluripotent stem cells using recombinant proteins. Cell Stem Cell. 2009, 4: 381-384. 10.1016/j.stem.2009.04.005.View ArticlePubMedGoogle Scholar
- Gonzalez F, Boue S, Izpisua Belmonte JC: Methods for making induced pluripotent stem cells: reprogramming a la carte. Nat Rev Genet. 2011, 12: 231-242.View ArticlePubMedGoogle Scholar
- Worsdorfer P, Thier M, Kadari A, Edenhofer F: Roadmap to cellular reprogramming – manipulating transcriptional networks with DNA, RNA, proteins and small molecules. Curr Mol Med. 2011, 13: 868-878.View ArticleGoogle Scholar
- Sommer CA, Mostoslavsky G: Experimental approaches for the generation of induced pluripotent stem cells. Stem Cell Res Ther. 2010, 1: 26-10.1186/scrt26.PubMed CentralView ArticlePubMedGoogle Scholar
- Carey BW, Markoulaki S, Hanna J, Saha K, Gao Q, Mitalipova M, Jaenisch R: Reprogramming of murine and human somatic cells using a single polycistronic vector. Proc Natl Acad Sci U S A. 2009, 106: 157-162. 10.1073/pnas.0811426106.PubMed CentralView ArticlePubMedGoogle Scholar
- Szymczak AL, Workman CJ, Wang Y, Vignali KM, Dilioglou S, Vanin EF, Vignali DA: Correction of multi-gene deficiency in vivo using a single ‘self-cleaving’ 2A peptide-based retroviral vector. Nat Biotechnol. 2004, 22: 589-594. 10.1038/nbt957.View ArticlePubMedGoogle Scholar
- Soldner F, Hockemeyer D, Beard C, Gao Q, Bell GW, Cook EG, Hargus G, Blak A, Cooper O, Mitalipova M, Isacson O, Jaenisch R: Parkinson’s disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell. 2009, 136: 964-977. 10.1016/j.cell.2009.02.013.PubMed CentralView ArticlePubMedGoogle Scholar
- Sommer CA, Stadtfeld M, Murphy GJ, Hochedlinger K, Kotton DN, Mostoslavsky G: Induced pluripotent stem cell generation using a single lentiviral stem cell cassette. Stem Cells. 2009, 27: 543-549. 10.1634/stemcells.2008-1075.View ArticlePubMedGoogle Scholar
- Staerk J, Dawlaty MM, Gao Q, Maetzel D, Hanna J, Sommer CA, Mostoslavsky G, Jaenisch R: Reprogramming of human peripheral blood cells to induced pluripotent stem cells. Cell Stem Cell. 2010, 7: 20-24. 10.1016/j.stem.2010.06.002.PubMed CentralView ArticlePubMedGoogle Scholar
- Somers A, Jean JC, Sommer CA, Omari A, Ford CC, Mills JA, Ying L, Sommer AG, Jean JM, Smith BW, Lafyatis R, Demierre MF, Weiss DJ, French DL, Gadue P, Murphy GJ, Mostoslavsky G, Kotton DN: Generation of transgene-free lung disease-specific human induced pluripotent stem cells using a single excisable lentiviral stem cell cassette. Stem Cells. 2010, 28: 1728-1740. 10.1002/stem.495.PubMed CentralView ArticlePubMedGoogle Scholar
- Awe JP, Lee PC, Ramathal C, Vega-Crespo A, Durruthy-Durruthy J, Cooper A, Karumbayaram S, Lowry WE, Clark AT, Zack JA, Sebastiano V, Kohn DB, Pyle AD, Martin MG, Lipshutz GS, Phelps PE, Pera RA, Byrn JA: Generation and characterization of transgene-free human induced pluripotent stem cells and conversion to putative clinical-grade status. Stem Cell Res Ther. 2013, 4: 87-10.1186/scrt246.PubMed CentralView ArticlePubMedGoogle Scholar
- Loh YH, Yang JC, De Los Angeles A, Guo C, Cherry A, Rossi DJ, Park IH, Daley GQ: Excision of a viral reprogramming cassette by delivery of synthetic Cre mRNA. Curr Protoc Stem Cell Biol. 2012, Chapter 4: Unit4A 5-PubMedGoogle Scholar
- Patsch C, Edenhofer F: Conditional mutagenesis by cell-permeable proteins: potential, limitations and prospects. Handb Exp Pharmacol. 2007, 178: 203-232. 10.1007/978-3-540-35109-2_9.View ArticlePubMedGoogle Scholar
- Haupt S, Edenhofer F, Peitz M, Leinhaas A, Brustle O: Stage-specific conditional mutagenesis in mouse embryonic stem cell-derived neural cells and postmitotic neurons by direct delivery of biologically active Cre recombinase. Stem Cells. 2007, 25: 181-188. 10.1634/stemcells.2006-0371.View ArticlePubMedGoogle Scholar
- Nolden L, Edenhofer F, Haupt S, Koch P, Wunderlich FT, Siemen H, Brustle O: Site-specific recombination in human embryonic stem cells induced by cell-permeant Cre recombinase. Nat Methods. 2006, 3: 461-467. 10.1038/nmeth884.View ArticlePubMedGoogle Scholar
- Peitz M, Jager R, Patsch C, Jager A, Egert A, Schorle H, Edenhofer F: Enhanced purification of cell-permeant Cre and germline transmission after transduction into mouse embryonic stem cells. Genesis. 2007, 45: 508-517. 10.1002/dvg.20321.View ArticlePubMedGoogle Scholar
- Peitz M, Pfannkuche K, Rajewsky K, Edenhofer F: Ability of the hydrophobic FGF and basic TAT peptides to promote cellular uptake of recombinant Cre recombinase: a tool for efficient genetic engineering of mammalian genomes. Proc Natl Acad Sci U S A. 2002, 99: 4489-4494. 10.1073/pnas.032068699.PubMed CentralView ArticlePubMedGoogle Scholar
- Russ HA, Bar Y, Ravassard P, Efrat S: In vitro proliferation of cells derived from adult human beta cells revealel by cell lineage tracing. Diabetes. 2008, 57: 1575-1583. 10.2337/db07-1283.View ArticlePubMedGoogle Scholar
- Muller FJ, Schuldt BM, Williams R, Mason D, Altun G, Papapetrou EP, Danner S, Goldmann JE, Herbst A, Schmidt NO, Aldenhoff JB, Laurent LC, Loring JF: A bioinformatic assay for pluripotency in human cells. Nat Methods. 2011, 8: 315-317. 10.1038/nmeth.1580.PubMed CentralView ArticlePubMedGoogle Scholar
- Carpenter L, Carr C, Yang CT, Stuckey DJ, Clarke K, Watt SM: Efficient differentiation of human induced pluripotent stem cells generates cardiac cells that provide protection following myocardial infarction in the rat. Stem Cells Dev. 2012, 21: 977-986. 10.1089/scd.2011.0075.PubMed CentralView ArticlePubMedGoogle Scholar
- Moran DM, Shen H, Maki CG: Puromycin-based vectors promote a ROS-dependent recruitment of PML to nuclear inclusions enriched with HSP70 and Proteasomes. BMC Cell Biol. 2009, 10: 32-10.1186/1471-2121-10-32.PubMed CentralView ArticlePubMedGoogle Scholar
- Glover DJ, Lipps HJ, Jans DA: Towards safe, non-viral therapeutic gene expression in humans. Nat Rev Genet. 2005, 6: 299-310. 10.1038/nrg1577.View ArticlePubMedGoogle Scholar
- Willmann CA, Hemeda H, Pieper LA, Lenz M, Qin J, Joussen S, Sontag S, Wanek P, Denecke B, Schuler HM, Zenke M, Wagner W: To clone or not to clone? Induced pluripotent stem cells can be generated in bulk culture. PLoS One. 2013, 8: e65324-10.1371/journal.pone.0065324.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.